Hereditary Angioedema Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Hereditary Angioedema Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Hereditary angioedema is an inherited condition characterized by re-occurant severe swelling. It affects arms, face, legs, airway and intestinal tract commonly. Having low level of C1 inhibitor, which is a protein that leads to excess activation of bradykinin which is a primary reason for angioedema. There are three types of hereditary angioedema Type-I, Type-II and Type-III. Type-I is characterised by low levels of C-1 inhibitor whereas Type -II characterised by normal or high levels of C-1 inhibitor. Type-III pathology is unknown. Usually symptoms will begin from puberty but may be seen even earlier. Minor trauma or stress may trigger the attack, however, swelling often occurs without a known trigger. Angioedema occurs in intestinal tract may lead to severe abdominal pain, nausea, and vomiting. Swelling in airway can obstruct passage of air and may lead to life threatening condition.

Global hereditary angioedema treatment market is mainly driven by increase in R&D to treat angioedema. In addition, increase in prevalence and promising pipeline are expected to boost the hereditary angioedema treatment market. Furthermore, change in lifestyle, improved reimbursement infrastructure, and healthcare spending are expected to bolster the hereditary angioedema treatment market. However, high cost of prophylaxis and misdiagnosis of the condition are expected to hinder the hereditary angioedema treatment market during the forecast period.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/#ulp-4H8Z4LpNMLEuOnnx


Hereditary angioedema treatment market has been segmented based on type, drug class, and distribution channel

Base on type, hereditary angioedema treatment market is segmented into
• Type-I
• Type-II
• Type-III

Based on drug class, hereditary angioedema treatment market is segmented into
• C1 esterase inhibitors
• Plasma kallikrein inhibitors (Ecallantide)
• Bradykinin receptor antagonists (Icatibant)
• Corticosteroids
• Antihistamines
• Autoimmune drugs
• Blood protein controllers
• Antifibrinolytic agents

Based on distribution channel, hereditary angioedema treatment market is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/#ulp-c654SbFYO64MsOhu


Hereditary angioedema treatment market has expected to show healthy growth rate during forecast period. The market has many promising pipeline drugs and prophylaxis to treat hereditary angioedema. For instance, BioCryst Pharmaceuticals is in the process of developing a lead molecule known as BCX7353 to prevent an angioedema that attacks especially the patients suffering from hereditary angioedema and it has completed phase-II clinical trials. BioCryst pharmaceuticals received initial regulatory approvals in Europe to initiate the ZENITH-1 (clinical trail to study BCX7353) exploratory clinical trial in 2017. Shire plc is also conducting a post marketing investigation of drug Firazyr in countries where it is approved for hereditary angioedema attacks. Collaborations and acquisitions are key market strategies adopted by the market players. Companies also collaborating with research and non-profit organizations for better outcomes in treatment. For instance, in April 2017, PatientsLikeMe, a patient network and real-time research platform and Shire plc have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of patient health and disease. Licensing is also a key strategy in hereditary treatment market. For instance, in August 2016, Pharming Group NV, acquired back all North American commercialization rights to ruconest from Valeant Pharmaceuticals International, Inc.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/#ulp-14mlyhjMGhVjZqa3


Geographically hereditary angioedema treatment market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to grow at significant growth rate due to lifestyle changes, increase in prevalence and growth in the diagnosis of hereditary angioedema in U.S. region. According to WHO, incidence rate of HAE is 1/10,000–50,000 people in United States and Canada in 2015 and Mortality rates are estimated as 15–33%. Asia-Pacific expected to be fastest growing owing to increase in awareness about the disease conditions, developing healthcare infrastructure and lifestyle changes.

Some of the players in hereditary angioedema treatment market are BioCryst Pharmaceuticals, Inc. (U.S), CSL Limited (Australia), Pharming Group NV (Netherlands), Salix Pharmaceuticals (U.S), and Shire (Republic of Ireland) to name a few.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.